Skip Navigation LinksHome > Published Ahead-of-Print > Transperineal Template-guided Mapping Biopsy Identifies Path...
American Journal of Clinical Oncology:
doi: 10.1097/COC.0000000000000105
Original Article: PDF Only

Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Very-Low-risk and Low-risk Prostate Cancer: Implications for Active Surveillance.

Merrick, Gregory S. MD; Delatore, Alexandra BS; Butler, Wayne M. PhD; Bennett, Abbey BS; Fiano, Ryan MPH; Anderson, Richard BS; Adamovich, Edward MD

Published Ahead-of-Print
Collapse Box

Abstract

Objectives: Active surveillance (AS) is increasingly utilized for low-grade prostate cancer with the greatest risk being the possibility of missing a high-grade cancer. We evaluate the role of transperineal template-guided mapping biopsy (TTMB) to select patients for AS.

Methods: A total of 131 consecutive, prospectively evaluated men with transrectal ultrasound-guided needle biopsy (TRUS)-diagnosed very low risk (Gleason score <=6, <=2 positive biopsies, prostate-specific antigen [PSA] density <0.15, and <=50% involvement on any core) and low risk (Gleason score <=6, clinical stage T1c, and PSA <=10 ng/mL) underwent TTMB as a staging procedure. Biopsies were obtained corresponding to 24 regional biopsy locations. For each patient, the location of each positive biopsy core, the number of positive cores, and the percentage involvement of each core were reported.

Results: After TTMB, TRUS-detected very-low-risk prostate cancer patients were less likely to be diagnosed with higher Gleason score, were less likely to have bilateral involvement, and had statistically fewer number of positive biopsy cores on TTMB. After TTMB, no cancer, very-low-risk, or low-risk prostate cancer was detected in 60 of 72 (83.3%) and 19 of 59 (32.2%) of patients with very low and low risk, respectively. In multivariate analysis, older age and low risk predicted for higher Gleason score at the time of TTMB.

Conclusions: Very-low-risk prostate cancer patients have a significantly lower incidence of Gleason score upgrading than those with low-risk disease. After TTMB, 83.3% of patients with very-low-risk and 32.2% of patients with low-risk disease appear to be outstanding candidates for AS.

(C) 2014 by Lippincott Williams & Wilkins, Inc

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/AJCOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.